PD‐L1, being widely used as an immunotherapy marker in clinics, has prompted the development of numerous nuclear imaging probes for therapeutic efficacy prediction in both preclinical and clinical contexts.[11] In a landmark study by Heskamp et al.[12] in 2015, 111In‐labeled αPD‐L1 was employed for imaging PD‐L1 in tumor models. Here, CD274 is linked to neoplasm.